Verastem (NASDAQ:VSTM - Get Free Report) had its target price increased by equities researchers at Royal Bank of Canada from $13.00 to $16.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Royal Bank of Canada's price objective suggests a potential upside of 153.57% from the company's current price.
VSTM has been the subject of a number of other reports. StockNews.com lowered shares of Verastem from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. Guggenheim began coverage on shares of Verastem in a research note on Monday, September 30th. They set a "buy" rating and a $13.00 target price for the company. Mizuho boosted their price target on shares of Verastem from $7.00 to $9.00 and gave the stock an "outperform" rating in a research note on Thursday, December 19th. BTIG Research raised their price objective on Verastem from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Finally, HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Verastem in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $13.38.
Get Our Latest Report on Verastem
Shares of VSTM stock traded down $0.41 on Tuesday, hitting $6.31. 542,714 shares of the stock traded hands, compared to its average volume of 3,602,768. The firm has a market cap of $280.84 million, a price-to-earnings ratio of -1.98 and a beta of 0.24. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.23 and a quick ratio of 3.23. The firm has a 50 day simple moving average of $4.49 and a two-hundred day simple moving average of $3.40. Verastem has a 52 week low of $2.10 and a 52 week high of $14.22.
Verastem (NASDAQ:VSTM - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.11. As a group, equities research analysts predict that Verastem will post -3.16 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VSTM. Walleye Capital LLC increased its position in shares of Verastem by 493.7% during the 3rd quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company's stock valued at $646,000 after purchasing an additional 179,725 shares during the last quarter. Nantahala Capital Management LLC bought a new position in Verastem during the second quarter valued at $1,192,000. XTX Topco Ltd purchased a new stake in shares of Verastem in the third quarter valued at $112,000. SG Americas Securities LLC bought a new stake in shares of Verastem in the 3rd quarter worth about $43,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Verastem by 46.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 103,601 shares of the biopharmaceutical company's stock worth $310,000 after purchasing an additional 32,791 shares during the period. 88.37% of the stock is currently owned by hedge funds and other institutional investors.
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Verastem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.
While Verastem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.